Citigroup Inc Aerovate Therapeutics, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 233,411 shares of AVTE stock, worth $597,532. This represents 0.0% of its overall portfolio holdings.

Number of Shares

233,411

Previous 3,545 6484.23%

Holding current value

$597,532

Previous $5,000 9640.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$1.61 - $2.09 $370,084 - $480,419	229,866 Added 6484.23%	233,411 $487,000
Q2 2024 Aug 12, 2024	BUY	$1.41 - $30.75 $1,407 - $30,688	998 Added 39.18%	3,545 $5,000
Q1 2024 May 10, 2024	BUY	$17.68 - $29.57 $7,991 - $13,365	452 Added 21.58%	2,547 $75,000
Q4 2023 Feb 09, 2024	BUY	$9.58 - $24.25 $18,029 - $45,638	1,882 Added 883.57%	2,095 $47,000
Q3 2023 Nov 09, 2023	SELL	$12.9 - $18.88 $40,131 - $58,735	-3,111 Reduced 93.59%	213 $2,000
Q2 2023 Aug 10, 2023	BUY	$15.63 - $22.01 $48,374 - $68,120	3,095 Added 1351.53%	3,324 $57,000
Q1 2023 May 11, 2023	SELL	$19.17 - $27.7 $2,300 - $3,324	-120 Reduced 34.38%	229 $4,000
Q4 2022 Feb 09, 2023	SELL	$15.92 - $30.52 $2,531 - $4,852	-159 Reduced 31.3%	349 $10,000
Q3 2022 Nov 10, 2022	SELL	$14.77 - $25.79 $8,418 - $14,700	-570 Reduced 52.88%	508 $8,000
Q2 2022 Aug 10, 2022	SELL	$10.8 - $16.91 $3,693 - $5,783	-342 Reduced 24.08%	1,078 $17,000
Q1 2022 May 12, 2022	SELL	$8.25 - $18.33 $16,896 - $37,539	-2,048 Reduced 59.05%	1,420 $26,000
Q4 2021 Feb 10, 2022	BUY	$9.14 - $21.54 $21,195 - $49,951	2,319 Added 201.83%	3,468 $41,000
Q3 2021 Nov 10, 2021	BUY	$11.76 - $22.49 $13,512 - $25,841	1,149 New	1,149 $24,000

Others Institutions Holding AVTE

# of Institutions

Shares Held

28.1M

Call Options Held

116K

Put Options Held

26.6K

View Full List

About Aerovate Therapeutics, Inc.

Ticker AVTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,448,100
Market Cap $62.6M
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...

More about AVTE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account